BRAF V600E mutation in papillary thyroid carcinoma: Prevalence and detection in fine needle aspiration specimens;Mutation BRAF V600E et carcinomes papillaires de la thyroïde: Prévalence et faisabilité de la détection sur produits de cytoponction

Annales de Pathologie

Volumn 30, Issue 4, 2010, Pages 252-262

  Dujardin, Fanny ^a   Pagès, Jean Christophe ^a   Collin, Christine ^a   de Calan, Loïc ^a   Lecomte, Pierre ^b   Guyétant, Serge ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b CHU BRETONNEAU   (France)

Author keywords

BRAF V600E mutation; Papillary thyroid carcinoma; Thyroid fine needle aspiration

Indexed keywords

B RAF KINASE;

ARTICLE; ASPIRATION BIOPSY; CANCER DIAGNOSIS; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; HUMAN; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; PREOPERATIVE EVALUATION; PREVALENCE; THYROID CARCINOMA; THYROIDECTOMY;

BIOPSY; BIOPSY, FINE-NEEDLE; CARCINOMA, PAPILLARY; FRANCE; HUMANS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 77956617853     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annpat.2010.05.011     Document Type: Article

References (51)

1. DeLellis RA, Lloyd RV, Heitz PU, et al. World Health Organization classification of tumours: pathology and genetics of tumours of endocrine organs. Lyon, France: IARC Press; 2004.
2. Syed ZA, Cibas ES. The Bethesda system for reporting thyroid cytopathology. Definitions, criteria and explanatory notes. New York: Springer; 2010.
3. Recommandations pour la pratique clinique: la prise en charge diagnostique du nodule thyroïdien. Ann Endocrinol 1996, 57:526-535. ANAES.
4. Gharib H., Goellner J.R. Fine needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med 1993, 118:282-289.
5. Lassale S., Hofman V., Butori C., Long E., Guevara N., Santini J., et al. Rôle du cytopathologiste dans la prise en charge d'un nodule thyroïdien. Revue francophone des laboratoires 2008, 398(38):37-44.
6. Vielh P., Mansuet-Lupo A., Polivka M., Saada M., Cochand-Priollet B. Le point sur l'immunocytochimie et sur son intérêt dans la prise en charge des nodules thyroïdiens. Ann Pathol 2006, 26:340-345.
7. Xing M. BRAF mutation in thyroid cancer (review). Endocr Relat Cancer 2005, 12:245-262.
8. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003, 63:1454-1457.
9. Soares P., Trovisco V., Rocha A.S., Lima J., Castro P., Preto A., et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003, 22:4578-4580.
10. Fukushima T., Suzuki S., Mashiko M., Ohtake T., Endo Y., Takebayashi Y., et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003, 22:6455-6457.
11. Frattini M., Ferrario C., Bressan P., Balestra D., De Cecco L., Mondellini P., et al. Alternative mutations of BRAF. RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004, 23:7436-7440.
12. Adeniran A.J., Zhu Z., Gandhi M., Steward D.L., Fidler J.P., Giordano T.J., et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006, 30:216-222.
13. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
14. Trovisco V., Vieira de Castro I., Soares P., Maximo V., Silva P., Magalhaes J., et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004, 202:247-251.
15. Nikiforova M.N., Kimura E.T., Gandhi M., Biddinger P.W., Knauf J.A., Basolo F., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003, 88:5399-5404.
16. Namba H., Nakashima M., Hayashi T., Hayashida N., Maeda S., Rogounovitch T.I., et al. Clinical implication of hot spot BRAF mutation. V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003, 88:4393-4397.
17. Xu X., Quiros R.M., Gattuso P., Ain K.B., Prinz R.A. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003, 63:4561-4567.
18. Xing M., Westra W.H., Tufano R.P., Cohen Y., Rosenbaum E., Rhoden K.J., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid carcinoma. J Clin Endocrinol Metab 2005, 90:6373-6379.
19. Xing M., Vasko V., Tallini G., Larin A., Wu G., Udelsman R., et al. BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 2004, 89:1365-1368.
20. Cohen Y., Xing M., Mambo E., Guo Z., Wu G., Trink B., et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003, 95:625-627.
21. Chung K.W., Yang S.K., Lee G.K., Kim E.Y., Kwon S., Lee S.H., et al. Detection of BRAF V600E mutation on fine needle aspiration specimens of thyroid nodule refines cytopathology diagnosis, especially in BRAF V600E mutation-prevalent area. Clin Endocrinol (Oxf) 2006, 65:660-666.
22. Kim S., Kim D.L., Han H.S., Kim W.S., Kim Seung J., Moon W.J., et al. Pyrosequencing analysis for detection of a BRAF V600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 2008, 17:118-125.
23. Kondo T., Ezzat S., Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev 2006, 6:292-306.
24. Lacroix L., Soria J.C., Bidart J.M., Schlumberger M. Oncogenes and thyroid tumors. Bull Cancer 2005, 92:37-43.
25. Lupi C., Giannini R., Ugolini C., Proietti A., Berti P., Minuto M., et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007, 92:4085-4090.
26. Trovisco V., Soares P., Preto A., de Castro I.V., Lima J., Castro P., et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 2005, 446:589-595.
27. Knauf J.A., Ma X., Smith E.P., Zhang L., Mitsutake N., Nikiforov Y.E., et al. Targeted expression of BRAF-V600E in thyroid cells of trangenic mice results in papillary thyroid cancers that transition to undifferentiated carcinomas. Cancer Res 2005, 65:4238-4245.
28. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007, 28:742-762.
29. Goutas N., Vlachodimitropoulos D., Bouka M., Lazaris A.C., Nasioulas G., Gazouli M. BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res 2008, 28:305-308.
30. Kumagai A., Namba H., Akanov Z., Saenko V.A., Meirmanov S., Ohtsuru A., et al. Clinical implications of preoperative rapid BRAF analysis for papillary thyroid cancer. Endocr J 2007, 54:399-405.
31. Sapio M.R., Posca D., Raggioli A., Guerra A., Marotta V., Deandrea M., et al. Detection of RET/PTC. TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocr 2007, 66:678-683.
32. Hayashida N., Namba H., Kumagai A., Hayashi T., Ohtsuru A., Ito M., et al. A rapid and simple detection method for the BRAF (T1796A) mutation in fine-needle aspirated thyroid carcinoma cells. Thyroid 2004, 14:910-915.
33. Cohen Y., Rosenbaum E., Clark D.P., Zeiger M.A., Umbricht C.B., Tufano R.P., et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004, 10:2761-2765.
34. Abrosimov A., Saenko V., Rogounovitch T., Namba H., Lushnikov E., Mitsutake N., et al. Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int J Cancer 2006, 120:196-200.
35. Unger K., Zitzelsberger H., Salvatore G., Santoro M., Bogdanova T., Braselmann H., et al. Heterogeneity in the distribution of RET/PTC rearrangements within individual post-chernobyl papillary thyroid carcinomas. J Clin Endocrinol Metab 2004, 89:4272-4279.
36. Jovanovic L., Delahunt B., McIver B., Eberhardt N.L., Grebe S.K. Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intraglandular spread of the initial neoplastic clone. J Pathol 2008, 215:145-154.
37. Watanabe R., Hayashi Y., Sassa M., Kikumori T., Imai T., Kiuchi T., et al. Possible involvement of BRAF V600E in altered gene expression in papillary thyroid cancer. Endocr J 2009, 56(3):407-414.
38. Vasko V., Hu S., Wu G., Xing J.C., Larin A., Savchenko V., et al. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 2005, 90:5265-5269.
39. Trovisco V., Soares P., Sobrinho-Simões M. BRAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol 2006, 37:781-786.
40. Nikiforov Y.E. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008, 21(Suppl. 2):S37-S43.
41. Fugazzola L., Puxeddu E., Avenia N., Romei C., Cirello V., Cavaliere A., et al. Correlation between BRAF V600E mutation and clinicopathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006, 13:455-464.
42. Lee J.H., Lee E.S., Kim Y.S. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007, 110:38-46.
43. Santarpia L., Sherman S.I., Marabotti A., Clayman G.L., El-Naggar A.K. Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Hum Pathol 2009, 40:827-833.
44. Jin L., Sebo T.J., Nakamura N., Qian X., Oliveira A., Majerus J.A., et al. BRAF mutation analysis in fine needle aspiration (FNAB) cytology of the thyroid. Diagn Mol Pathol 2006, 15:136-143.
45. Elisei R., Ugolini C., Viola D., Lupi C., Biagini A., Giannini R., et al. BRAF (V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008, 93:3943-3949.
46. Henderson Y.C., Shellenberger T.D., Williams M.D., El-Naggar A.K., Fredrick M.J., Cieply K.M., et al. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res 2009, 15:485-491.
47. Rowe L.R., Bentz B.G., Bentz J.S. Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal 2006, 3:10.
48. Salvatore G., Giannini R., Faviana P., Caleo A., Migliaccio I., Fagin J., et al. Analysis of BRAF point mutation and RET/PTC rearrangements refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2004, 89:5175-5180.
49. Pizzolanti G., Russo L., Richiusa P., Bronte V., Nuara R.B., Rodolico V., et al. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid 2007, 17:1109-1115.
50. Marchetti I., Lessi F., Mazzanti C.M., Bertacca G., Elisei R., Di Coscio G., et al. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid 2009, 19:837-842.
51. Xing M., Tufano R.P., Tufaro A.P., Basaria S., Ewertz M., Rosenbaum E., et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 2004, 89:2867-2872.